Esperion Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes

 Esperion Announces Positive Topline Results from a Phase 2 Clinical Trial of
                  ETC-1002 in Patients with Type 2 Diabetes

Data show LDL-C lowering of up to 43% and beneficial effects on other relevant
cardiometabolic risk factors to be presented at a future scientific meeting.

PR Newswire

PLYMOUTH, Mich., Jan 7, 2013

PLYMOUTH, Mich., Jan 7, 2013 /PRNewswire/ --Esperion Therapeutics, the
leading developer of small molecule therapies for the treatment of
cardiometabolic disorders, today announced positive results of a recently
completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes
with LDL-C lowering of up to 43% compared to placebo. ETC-1002 therapy was
also associated with improvements in control of additional cardiometabolic
risk factors in this high-risk, difficult-to-treat patient population. The
full data from this Phase 2 clinical trial will be presented at a future
scientific meeting.

ETC-1002 is an investigational, once-daily, oral small molecule therapy that
has been shown to be liver selective for activation of AMP kinase and
inhibition of ATP citrate lyase. This dual mechanism of action has the
potential to regulate imbalances in both hepatic lipid and carbohydrate
metabolism. In the Phase 2 trial, 60 patients with type 2 diabetes received
ETC-1002 or placebo for four weeks in an inpatient facility. In clinical
research to date, ETC-1002 has shown an attractive safety profile, significant
and consistent LDL-C lowering and beneficial effects on hsCRP, glucose and
other cardiometabolic risk factors. ETC-1002 is currently being studied in
multiple Phase 2 clinical trials.

"With these results, ETC-1002 has now been shown to be safe and well-tolerated
in two Phase 2 studies. We continue to rapidly advance ETC-1002 through Phase
2 clinical development and we are exploring its efficacy in additional patient
populations, with a particular focus on the growing statin-intolerant patient
population. We look forward to presenting our clinical results in
peer-reviewed settings later this year," said Tim Mayleben, president and CEO
of Esperion.

"People living with type 2 diabetes are at high risk for cardiovascular
disease. For many, treatment with statins and other cardiometabolic therapies
can impair glycemic control, potentially putting them at increased risk. With
a novel mechanism of action designed to lower LDL-C and provide beneficial
effects on glucose control, ETC-1002 has the potential to offer significant
advantages for patients living with type 2 diabetes and for patients who are
statin intolerant and/or not at the appropriate National Cholesterol Education
Program (NCEP) LDL-C goal," said Dr. Roger Newton, executive chairman and
chief scientific officer of Esperion.

About Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops novel therapies for the
treatment of cardiometabolic diseases. The company's lead product candidate,
ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is
being evaluated in multiple Phase 2 clinical trials for the treatment of
hypercholesterolemia and other cardiometabolic risk factors. Esperion intends
to commercialize innovative, first-in-class therapies focused on enhancing
lipid regulation, addressing statin intolerance and improving overall
cardiometabolic health. For more information, please visit www.esperion.com.

SOURCE Esperion Therapeutics

Website: http://www.esperion.com
Contact: Andrea Coan, Berry & Company Public Relations, +1-212-253-8881,
acoan@berrypr.com
 
Press spacebar to pause and continue. Press esc to stop.